Ghent University Academic Bibliography

Advanced

Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk

Yuanjun Ma and Nele Brusselaers UGent (2018) PROSTATE CANCER AND PROSTATIC DISEASES. 21(1). p.147-152
abstract
Background: Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may have a preventive effect against prostate cancer. However, evidence is limited and still controversial, especially considering non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs). Methods: Swedish nationwide population-based cohort study including all long-term (>= 180 days) adult male users of aspirin (n = 419,931) or NSAIDs (n = 223,437) followed from the first dispense date until the first cancer diagnosis, death or 31 December 2012, whichever occurred first. The risk of prostate cancer was measured as standardized incidence ratios (SIR) and 95% confidence intervals (CI), assessing duration of use, age and concomitant statins intake, comparing to the general male background population of the same age in Sweden. Results: The overall SIR suggests that maintenance use of aspirin decreases the risk of prostate cancer (SIR = 0.87, 95% CI 0.85-0.88), in particular if used >= 5 years (SIR = 0.31, 95% CI 0.30-0.32). The overall risk was decreased (SIR = 0.87, 95% CI 0.85-0.90) among other NSAIDs users, and again in particular among longer-term users (>= 3 years) with SIR = 0.58 (95% CI 0.53-0.63). When statins users were excluded from all aspirin users, there was no remaining association with prostate cancer (SIR = 0.99, 95% CI 0.96-1.02), only if taken >= 5 years (SIR = 0.31, 95% CI 0.29-0.34). For non-aspirin NSAIDs users, the protective effect remained after exclusion of statins users (SIR = 0.92, 95% CI 0.88-0.95). Conclusions: This population-based cohort study provides evidence for a protective effect of aspirin and other NSAIDs against prostate cancer, in particular for longer durations of use, yet concomitant use of statins strongly influences the risk among aspirin users.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
STATIN USE, INFLAMMATION, PREVENTION, RAT, CYCLOOXYGENASE-2, METAANALYSIS, BIOPSY, REDUCE, TRIAL, MEN
journal title
PROSTATE CANCER AND PROSTATIC DISEASES
Prostate Cancer Prostatic Dis.
volume
21
issue
1
pages
147 - 152
Web of Science type
Article
Web of Science id
000430152800017
ISSN
1365-7852
1476-5608
DOI
10.1038/s41391-017-0021-x
language
English
UGent publication?
no
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
8548976
handle
http://hdl.handle.net/1854/LU-8548976
date created
2018-02-09 13:01:36
date last changed
2018-05-14 09:24:50
@article{8548976,
  abstract     = {Background: Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may have a preventive effect against prostate cancer. However, evidence is limited and still controversial, especially considering non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs). 
Methods: Swedish nationwide population-based cohort study including all long-term ({\textrangle}= 180 days) adult male users of aspirin (n = 419,931) or NSAIDs (n = 223,437) followed from the first dispense date until the first cancer diagnosis, death or 31 December 2012, whichever occurred first. The risk of prostate cancer was measured as standardized incidence ratios (SIR) and 95\% confidence intervals (CI), assessing duration of use, age and concomitant statins intake, comparing to the general male background population of the same age in Sweden. 
Results: The overall SIR suggests that maintenance use of aspirin decreases the risk of prostate cancer (SIR = 0.87, 95\% CI 0.85-0.88), in particular if used {\textrangle}= 5 years (SIR = 0.31, 95\% CI 0.30-0.32). The overall risk was decreased (SIR = 0.87, 95\% CI 0.85-0.90) among other NSAIDs users, and again in particular among longer-term users ({\textrangle}= 3 years) with SIR = 0.58 (95\% CI 0.53-0.63). When statins users were excluded from all aspirin users, there was no remaining association with prostate cancer (SIR = 0.99, 95\% CI 0.96-1.02), only if taken {\textrangle}= 5 years (SIR = 0.31, 95\% CI 0.29-0.34). For non-aspirin NSAIDs users, the protective effect remained after exclusion of statins users (SIR = 0.92, 95\% CI 0.88-0.95). 
Conclusions: This population-based cohort study provides evidence for a protective effect of aspirin and other NSAIDs against prostate cancer, in particular for longer durations of use, yet concomitant use of statins strongly influences the risk among aspirin users.},
  author       = {Ma, Yuanjun and Brusselaers, Nele},
  issn         = {1365-7852},
  journal      = {PROSTATE CANCER AND PROSTATIC DISEASES},
  keyword      = {STATIN USE,INFLAMMATION,PREVENTION,RAT,CYCLOOXYGENASE-2,METAANALYSIS,BIOPSY,REDUCE,TRIAL,MEN},
  language     = {eng},
  number       = {1},
  pages        = {147--152},
  title        = {Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk},
  url          = {http://dx.doi.org/10.1038/s41391-017-0021-x},
  volume       = {21},
  year         = {2018},
}

Chicago
Ma, Yuanjun, and Nele Brusselaers. 2018. “Maintenance Use of Aspirin or Other Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Prostate Cancer Risk.” Prostate Cancer and Prostatic Diseases 21 (1): 147–152.
APA
Ma, Yuanjun, & Brusselaers, N. (2018). Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. PROSTATE CANCER AND PROSTATIC DISEASES, 21(1), 147–152.
Vancouver
1.
Ma Y, Brusselaers N. Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. PROSTATE CANCER AND PROSTATIC DISEASES. 2018;21(1):147–52.
MLA
Ma, Yuanjun, and Nele Brusselaers. “Maintenance Use of Aspirin or Other Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Prostate Cancer Risk.” PROSTATE CANCER AND PROSTATIC DISEASES 21.1 (2018): 147–152. Print.